Navigation Links
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Date:12/1/2011

TARRYTOWN, N.Y., Dec. 1, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a time change for the Company's presentation at the 2011 Deutsche Bank BioFEST scheduled for Monday, December 5, 2011.  The presentation is scheduled for 1:05 p.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through January 4, 2012. 

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.847.7799914.847.7640michael.aberman@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
2. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
3. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
4. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
5. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
6. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
7. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
8. Regeneron Reports Second Quarter 2011 Financial and Operating Results
9. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
10. Trading in Regeneron Common Stock Halted
11. Regeneron Reports First Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 According to ... Growth and Demand Forecast to 2022 - Industry Insights by ... Diagnostic Center and Others)" by P&S Market Research, the global ... in 2015, and it is expected to grow at a ... high slice type segment is expected to witness the faster ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology:
(Date:5/5/2016)... , ... May 05, 2016 , ... Derrin Doty Group ... families of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring ... year local girl who died suddenly due to complications from the flu, that they ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the Midwest ... getting employees to understand and use the free preventive care benefits available to them ... business groups of large, self-insured public and private employers, MBGH found that only 10% ...
(Date:5/5/2016)... ... May 05, 2016 , ... Standard ... veterinary professionals across the United States. The whole food nutrient solutions company can ... and giving dog, cat and horse owners’ peace of mind. With the increased ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer Camp ... along with his university coaching staff. Together they bring their winning Vandals coaching philosophy ... for youth players ages 5-13, and high school players. Session dates are as follows: ...
(Date:5/5/2016)... ... 05, 2016 , ... Chronic stress can have a silent, yet dangerous, impact ... immune system and increase inflammation, both of which raise the risk of heart attack ... disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other ...
Breaking Medicine News(10 mins):